Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
10 08 2021
Historique:
received: 27 07 2020
accepted: 23 07 2021
entrez: 11 8 2021
pubmed: 12 8 2021
medline: 24 8 2021
Statut: epublish

Résumé

Subclonal genetic heterogeneity and their diverse gene expression impose serious problems in understanding the behavior of cancers and contemplating therapeutic strategies. Here we develop and utilize a capture-based sequencing panel, which covers host hotspot genes and the full-length genome of human T-cell leukemia virus type-1 (HTLV-1), to investigate the clonal architecture of adult T-cell leukemia-lymphoma (ATL). For chronologically collected specimens from patients with ATL or pre-onset individuals, we integrate deep DNA sequencing and single-cell RNA sequencing to detect the somatic mutations and virus directly and characterize the transcriptional readouts in respective subclones. Characteristic genomic and transcriptomic patterns are associated with subclonal expansion and switches during the clinical timeline. Multistep mutations in the T-cell receptor (TCR), STAT3, and NOTCH pathways establish clone-specific transcriptomic abnormalities and further accelerate their proliferative potential to develop highly malignant clones, leading to disease onset and progression. Early detection and characterization of newly expanded subclones through the integrative analytical platform will be valuable for the development of an in-depth understanding of this disease.

Identifiants

pubmed: 34376672
doi: 10.1038/s41467-021-25101-9
pii: 10.1038/s41467-021-25101-9
pmc: PMC8355240
doi:

Substances chimiques

Receptor, Notch1 0
Receptors, Antigen, T-Cell 0
STAT3 Transcription Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4821

Informations de copyright

© 2021. The Author(s).

Références

Blood Adv. 2017 Jun 27;1(15):1195-1205
pubmed: 29296760
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Clin Cancer Res. 2014 Jun 1;20(11):2851-61
pubmed: 24727323
Nat Commun. 2019 Aug 14;10(1):3660
pubmed: 31413257
Hum Cell. 2016 Jul;29(3):122-9
pubmed: 26940204
Blood. 2006 Jun 1;107(11):4500-7
pubmed: 16484591
J Immunol. 2007 Mar 1;178(5):2623-9
pubmed: 17312100
Blood. 2015 Dec 10;126(24):2570-7
pubmed: 26361794
Nat Rev Genet. 2021 Jan;22(1):3-18
pubmed: 32807900
Blood. 2017 Mar 2;129(9):1071-1081
pubmed: 28115366
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13445-50
pubmed: 19651619
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Genome Res. 2018 Aug;28(8):1217-1227
pubmed: 29898899
J Virol. 2007 Jun;81(11):5714-23
pubmed: 17344291
Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
Cancer Cell. 2017 Nov 13;32(5):608-623.e9
pubmed: 29136506
Nat Commun. 2017 May 23;8:15264
pubmed: 28534499
Nature. 2019 Jul;571(7765):355-360
pubmed: 31270458
Cancer Discov. 2014 Oct;4(10):1154-67
pubmed: 25104330
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Leukemia. 2017 Nov;31(11):2532-2535
pubmed: 28811663
Blood. 2018 Oct 4;132(14):1507-1518
pubmed: 30104217
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Blood. 2018 Jan 11;131(2):215-225
pubmed: 29084771
Genome Biol. 2021 Apr 6;22(1):97
pubmed: 33823910
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980
pubmed: 28356514
Leukemia. 2021 Mar;35(3):764-776
pubmed: 32555298
Blood. 2004 Apr 1;103(7):2443-51
pubmed: 14592821
Nat Methods. 2014 Apr;11(4):396-8
pubmed: 24633410
Nat Rev Cancer. 2007 Apr;7(4):270-80
pubmed: 17384582
EMBO Rep. 2018 Dec;19(12):
pubmed: 30413482
Blood. 2020 Jun 4;135(23):2023-2032
pubmed: 32160278
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Front Microbiol. 2018 Jul 24;9:1686
pubmed: 30087673
J Clin Microbiol. 2015 Feb;53(2):587-96
pubmed: 25502533
Nat Genet. 2018 Apr;50(4):493-497
pubmed: 29610479
Trends Genet. 2017 Feb;33(2):155-168
pubmed: 28089370
Leukemia. 2013 Dec;27(12):2393-6
pubmed: 23860447
Cell. 2019 Mar 7;176(6):1265-1281.e24
pubmed: 30827681
Elife. 2021 Jan 27;10:
pubmed: 33501914
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
Blood. 2011 Mar 17;117(11):3113-22
pubmed: 21228324
Cancer Cell. 2012 Jan 17;21(1):121-35
pubmed: 22264793
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Virology. 2019 Nov;537:14-19
pubmed: 31425970
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Science. 2018 Apr 20;360(6386):331-335
pubmed: 29674595
Mol Cell. 2019 Mar 21;73(6):1292-1305.e8
pubmed: 30765193
Retrovirology. 2020 Jan 8;17(1):2
pubmed: 31915026
Blood. 2016 Sep 15;128(11):1490-502
pubmed: 27369867
Cancer Sci. 2019 Dec;110(12):3746-3753
pubmed: 31642546
Blood. 2016 Apr 7;127(14):1790-802
pubmed: 26773042
Nat Methods. 2015 Jun;12(6):519-22
pubmed: 25915121
Cell Rep. 2019 Nov 19;29(8):2321-2337.e7
pubmed: 31747604

Auteurs

Makoto Yamagishi (M)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Miyuki Kubokawa (M)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Yuta Kuze (Y)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Ayako Suzuki (A)

Laboratory of Multi-Omics Data Analysis, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Akari Yokomizo (A)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Seiichiro Kobayashi (S)

Department of Hematology, Kanto Rosai Hospital, Kanagawa, Japan.

Makoto Nakashima (M)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Junya Makiyama (J)

Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan.

Masako Iwanaga (M)

Department of Clinical Epidemiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Takahiro Fukuda (T)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Toshiki Watanabe (T)

Department of Practical Management of Medical Information, Graduate School of Medicine, St. Marianna University, Kanagawa, Japan.

Yutaka Suzuki (Y)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ysuzuki@edu.k.u-tokyo.ac.jp.

Kaoru Uchimaru (K)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. uchimaru@edu.k.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH